Costopoulos Charis, Crowson Matthew C, Brown Adam J, Braganza Denise M, Bennett Martin R, Hoole Stephen P, West Nick E J
Division of Cardiovascular Medicine, University of Cambridge, UK; Department of Interventional Cardiology, Papworth Hospital NHS Trust, UK.
Department of Interventional Cardiology, Papworth Hospital NHS Trust, UK.
Cardiovasc Revasc Med. 2015 Dec;16(8):461-4. doi: 10.1016/j.carrev.2015.08.003. Epub 2015 Aug 15.
Available data on the use of the ABSORB bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA) in real-world patients is limited. The aim of this study was to assess the mid-term clinical outcomes in a real-world population treated with ABSORB BVS.
We retrospectively evaluated all patients treated with ABSORB at Papworth Hospital, Papworth Everard, UK between July 2012 and July 2014. A total of 108 patients (126 lesions) were identified. Clinical follow-up was performed on all subjects by clinic visit or telephone interview.
Most patients were male (91.7%) with a relative high incidence of previous myocardial infarction (MI) (40.7%). Clinical presentation was equally divided between stable angina and acute coronary syndrome (ACS) (51.8% vs. 48.2%, p=0.59). Of the ACS patients, 26.9% presented with ST-elevation myocardial MI. Intravascular imaging was used in all cases. Predilatation (92.9%) and postdilatation (82.5%) were frequently performed. Major adverse cardiac event (MACE) rates defined as the composite of all-cause death, follow-up MI and target vessel revascularization were 2.5% at 6-month and 4.5% at 1-year. The 1-year target lesion failure rate, defined as the composite of cardiac death, target-vessel MI and target lesion revascularization was 1.9%. There was 1 case of subacute stent thrombosis.
The use of ABSORB BVS in real-world patients appears to be associated with good mid-term clinical outcomes when guided by intravascular imaging. Larger studies are required to evaluate further the role of BVS in routine clinical practice and examine how this compares to metallic devices.
Available data on the use of the ABSORB BVS in real-world patients is limited. We retrospectively evaluated all patients treated with ABSORB BVS between July 2012 and July 2014. A total of 108 patients (126 lesions) were identified. Clinical presentation was equally divided between stable angina and acute coronary syndrome (51.8% vs. 48.2%, p=0.59). Predilatation (92.9%) and postdilatation (82.5%) were frequently performed. Estimated MACE rates at 6-month and 1-year were 2.5% and 4.5% respectively, with a 1-year TLF rate of 1.9%. These results suggest that the use of ABSORB BVS use in the real-world is associated with good mid-term clinical outcomes when guided by intravascular imaging.
关于在真实世界患者中使用ABSO RB生物可吸收血管支架（BVS）（雅培血管，加利福尼亚州圣克拉拉）的现有数据有限。本研究的目的是评估在接受ABSO RB BVS治疗的真实世界人群中的中期临床结局。
我们回顾性评估了2012年7月至2014年7月期间在英国帕普沃思埃弗拉德的帕普沃思医院接受ABSO RB治疗的所有患者。共识别出108例患者（126处病变）。通过门诊就诊或电话访谈对所有受试者进行临床随访。
大多数患者为男性（91.7%），既往心肌梗死（MI）发生率相对较高（40.7%）。临床表现稳定型心绞痛和急性冠状动脉综合征（ACS）各占一半（51.8%对48.2%，p = 0.59）。在ACS患者中，26.9%表现为ST段抬高型心肌梗死。所有病例均使用血管内成像。预扩张（92.9%）和后扩张（82.5%）经常进行。定义为全因死亡、随访期MI和靶血管血运重建的复合终点的主要不良心脏事件（MACE）发生率在6个月时为2.5%，1年时为4.5%。1年时定义为心源性死亡、靶血管MI和靶病变血运重建的复合终点的靶病变失败率为1.9%。有1例亚急性支架血栓形成。
在血管内成像引导下，在真实世界患者中使用ABSO RB BVS似乎与良好的中期临床结局相关。需要更大规模的研究来进一步评估BVS在常规临床实践中的作用，并检查其与金属器械相比的情况。
关于在真实世界患者中使用ABSO RB BVS的现有数据有限。我们回顾性评估了2012年7月至2014年7月期间接受ABSO RB BVS治疗的所有患者。共识别出108例患者（126处病变）。临床表现稳定型心绞痛和急性冠状动脉综合征各占一半（51.8%对48.2%，p = 0.59）。预扩张（92.9%）和后扩张（82.5%）经常进行。6个月和1年时的估计MACE发生率分别为2.5%和4.5%，1年时的靶病变失败率为1.9%。这些结果表明，在血管内成像引导下，在真实世界中使用ABSO RB BVS与良好的中期临床结局相关。
